PARIS, FRANCE, 21 AUGUST 2026

法国巴黎，2026年8月21日

– Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis.

– 益普生（Euronext: IPN；ADR: IPSEY）今日宣布，已完成对Kartos Therapeutics的收购。Kartos Therapeutics是一家临床阶段的生物制药公司，此次收购为其增添了处于骨髓纤维化III期临床开发阶段的后期MDM2抑制剂navtemadlin。

About navtemadlin

关于 navtemadlin

Navtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to ruxolitinib for patients with myelofibrosis who have a suboptimal response to ruxolitinib. The Phase III POIESIS study is evaluating whether the addition of navtemadlin could improve clinical outcomes compared with ruxolitinib alone in this patient population.

Navtemadlin 是一种在研的口服 MDM2 抑制剂，正在开发作为鲁索替尼的附加疗法，用于对鲁索替尼反应不佳的骨髓纤维化患者。III 期 POIESIS 研究正在评估在此类患者人群中，与单用鲁索替尼相比，加用 navtemadlin 是否能改善临床结局。

Early clinical data demonstrate navtemadlin has the potential to transform suboptimal responses to standard of care ruxolitinib into clinically meaningful responses in patients with intermediate and high risk TP53wt myelofibrosis, to provide both enhanced clinical outcomes and potential disease-modifying benefit.

早期临床数据表明，navtemadlin 有望将中间危和高危 TP53 野生型骨髓纤维化患者对标准治疗药物 ruxolitinib 的非理想反应转化为具有临床意义的反应，从而改善临床结局并可能带来疾病修饰获益。

.

。

About myelofibrosis

关于骨髓纤维化

Myelofibrosis is a myeloproliferative neoplasm, frequently linked to alterations in the JAK/STAT pathway, in which patients develop bone marrow fibrosis due to the abnormal proliferation of hematopoietic stem cells and secretion of fibrogenic cytokines. As marrow function declines, blood production shifts to other organs, most often the spleen, leading to splenomegaly.

骨髓纤维化是一种骨髓增殖性肿瘤，常与JAK/STAT通路的改变相关。由于造血干细胞异常增殖以及致纤维化细胞因子的分泌，患者会出现骨髓纤维化。随着骨髓功能衰退，造血活动转移至其他器官，最常见的是脾脏，从而导致脾肿大。

Myelofibrosis is characterized by bone marrow failure, fibrosis, splenomegaly and a high symptom burden that can significantly affect quality of life, including fatigue, night sweats and other progressive symptoms. It also carries a risk of transformation to acute myeloid leukemia. The median age at diagnosis is approximately 67–69 years and the condition affects around 1.5 per 100,000 people in the U.S.

骨髓纤维化的特征为骨髓衰竭、纤维化、脾肿大以及高症状负担，包括疲劳、盗汗和其他进行性症状，可显著影响生活质量。该病还存在转化为急性髓系白血病的风险。诊断时的中位年龄约为67至69岁，在美国的患病率约为每10万人中1.5例。

and Europe. Approximately 75–89% of patients are intermediate- or high-risk at diagnosis and more than 95% are TP53wt. Ruxolitinib, a JAK inhibitor, is the first-line standard of care; however, it is estimated that a significant proportion of patients have an initial suboptimal response and approximately 50%-75% discontinue treatment after three years.

以及欧洲。约75–89%的患者在诊断时属于中危或高危，且超过95%为TP53野生型。鲁索替尼是一种JAK抑制剂，为一线标准治疗方案；然而，据估计，相当比例的患者初始反应不佳，且约有50%–75%的患者在三年后停止治疗。

Median overall survival is typically one to two years after treatment discontinuation, underscoring the need for new strategies that can increase the number of patients that can achieve optimal clinical outcomes..

中位总生存期通常在治疗中止后的一到两年，这凸显了需要新的策略来增加能够实现最佳临床结果的患者数量。

About Ipsen

关于益普生

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K.

我们是一家全球性生物制药公司，专注于在肿瘤学、罕见病和神经科学三大治疗领域为患者带来变革性药物。我们的研发管线由内部和外部创新共同驱动，并依托近百年开发经验以及位于美国、法国和英国的全球研发中心提供支持。

Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries..

我们在40多个国家的团队以及遍布全球的合作伙伴关系，使我们能够将药品提供给100多个国家的患者。

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit

益普生在巴黎（泛欧交易所：IPN）和美国（通过一级有赞助的美国存托凭证计划，ADR代码：IPSEY）上市。欲了解更多信息，请访问

ipsen.com

ipsen.com

.

。

Ipsen Contacts

益普生联系方式

Investors

投资者

Henry Wheeler

亨利·惠勒

henry.wheeler@ipsen.com

henry.wheeler@ipsen.com

+33 7 66 47 11 49

+33 7 66 47 11 49

Khalid Deojee

哈立德·德奥吉

khalid.deojee@ipsen.com

khalid.deojee@ipsen.com

+33 6 66 01 95 26

+33 6 66 01 95 26

Media

媒体

Sally Bain

萨莉·贝恩

sally.bain@ipsen.com

sally.bain@ipsen.com

+1 857 320 0517

+1 857 320 0517

Anne Liontas

安妮·利翁塔斯

anne.liontas.ext@ipsen.com

anne.liontas.ext@ipsen.com

+33 7 67 34 72 96

+33 7 67 34 72 96

Disclaimers and/or forward-looking statements

免责声明及/或前瞻性陈述

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein.

本文所载的前瞻性陈述、目标和指标基于益普生（Ipsen）的管理层战略、当前观点和假设。此类陈述涉及已知和未知的风险与不确定性，可能导致实际结果、表现或事件与本文预期存在重大差异。

All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations.

上述所有风险均可能影响益普生未来实现其财务目标的能力，这些财务目标是在基于当前可用信息并假设宏观经济环境合理的背景下设定的。使用“相信”、“预计”和“预期”等词语及类似表述旨在识别前瞻性陈述，包括益普生对未来事件（含监管申报和裁定）的预期。

Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data.

此外，本文件中所述目标在编制时未考虑外部增长假设及潜在的未来收购事项，而这些因素可能会改变相关参数。这些目标基于依赛恩（Ipsen）认为合理的数据和假设。这些目标的实现取决于未来可能发生的情况或事实，而不仅仅依赖于历史数据。

Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons.

鉴于某些风险和不确定性的存在，实际结果可能与这些目标存在显著差异，尤其是处于早期开发阶段或临床试验阶段的有前景药物可能最终无法上市或实现其商业目标，这主要是出于监管或竞争方面的原因。

Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards t.

易普森必须面对或可能面临来自仿制药的竞争，这可能导致其市场份额流失。此外，研发过程包含多个阶段，每个阶段都存在重大风险，即易普森可能无法实现其目标，并被迫放弃相关努力。

ipsen.com

ipsen.com

.

。

Attachment

附件

Ipsen PR_Acquisition of Kartos Therapeutics_21082026

益普生公关_收购Kartos Therapeutics_2026年8月21日